setmelanotide peptide FDA‐approved drugs that target the MC4 receptor - Setmelanotidemechanism of action Setmelanotide is a small-peptide, melanocortin-4 receptor (MC4R) agonist Setmelanotide Peptide: A Targeted Therapy for Genetic Obesity

Setmelanotidevs semaglutide Setmelanotide peptide, marketed under the brand name Imcivree, represents a significant advancement in the treatment of specific genetic forms of obesityA) Structure of setmelanotide and bremelanotide,FDA‐approved drugs that target the MC4 receptor, and melanotan II, a synthetic cyclic analogue of α‐MSH.. This innovative peptide is a highly selective melanocortin 4 receptor (MC4R) agonist, designed to target a root cause of chronic weight gain in individuals with rare genetic mutations affecting the MC4R pathway. Unlike broader weight-loss medications, Setmelanotide is indicated for long-term weight management in patients, including adults and children aged 12 and older, diagnosed with obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) genes.

The mechanism of action for setmelanotide centers on its role as a cyclic peptide full agonist of melanocortin-4 receptor (MC4R). This receptor plays a crucial role in regulating appetite and energy balance.Setmelanotide is an 8 amino acid cyclic peptide analogof endogenous melanocortin peptide α-MSH (alpha-melanocyte stimulating hormone). The chemical name ... In individuals with specific genetic defects, the MC4R pathway is impaired, leading to excessive hunger and reduced satietySetmelanotide acetate | peptide-based agonist of .... Setmelanotide, as an analog of the endogenous melanocortin peptide $\alpha$-MSH (alpha-melanocyte stimulating hormone), effectively activates the MC4R. This activation can restore proper signaling, leading to improved satiety and ultimately, weight loss in severe obesity linked to these genetic conditions.Setmelanotide - LiverTox - NCBI Bookshelf - NIH Research has demonstrated its ability to rescue MC4R activity and treat obesities caused by these genetic defects in MC4R signaling.WO2019099735A1 - Sustained release peptide formulations

The efficacy and safety of Setmelanotide have been established through clinical trials. It is administered as a subcutaneous injection, with specific dosing regimens tailored to the patient's age and condition.Setmelanotide (RM-493)is a selective melanocortin 4 receptor (MC4R) agonistwith EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively. For adults and children aged 12 to 17 years, a typical starting dose is 1 mg once daily for two weeks. The drug is a peptide-based agonist of melanocortin 4 receptor (MC4R), and its precision in targeting the MC4R pathway distinguishes it from other weight management solutions. Studies have shown that setmelanotide can induce satiety and lead to reductions in body weight in patients with obesity secondary to rare genetic disorders. For instance, a meta-analysis evaluating the efficacy and safety of setmelanotide for weight loss in severe obesity linked to human MC4R deficiency highlighted its potential benefitsResults from a phase 2 trial showed thatsetmelanotide, an MC4R peptide agonist, reduced weight in 3 patients with LEPR deficiency obesity1. Setmelanotide Is ....

Key to understanding Setmelanotide's therapeutic profile is its chemical structure and properties. It is an 8 amino acid cyclic peptide analog of $\alpha$-MSH. Its high affinity for the MC4R is quantified by its EC50 values, which are remarkably low, indicating potent activation.Setmelanotide: A Melanocortin-4 Receptor Agonist for the ... For human MC4R, the EC50 is approximately 0.27 nM, and for rat MC4R, it's around 0.28 nMSetmelanotide - LiverTox - NCBI Bookshelf - NIH. This selectivity for the MC4R subtype, with approximately 20-fold selectivity over other melanocortin receptors, is crucial for its targeted action and minimizes off-target effects.

IMCIVREE is recognized as the first and only FDA-approved treatment specifically designed to target the impaired MC4R pathway, addressing a fundamental cause of obesity and hunger in affected individualsSetmelanotide is an 8 amino acid cyclic peptide analogof endogenous melanocortin peptide α-MSH (alpha-melanocyte stimulating hormone). The chemical name .... This makes Setmelanotide a groundbreaking therapy for conditions such as Bardet-Biedl syndrome and deficiencies in POMC. The drug's ability to provide a sustained release of setmelanotide is also an area of research, aiming to further optimize patient convenience and therapeutic outcomes.

While Setmelanotide is a powerful tool for genetic obesity, it's important to note its specific indications.WO2019099735A1 - Sustained release peptide formulations It is not a general weight-loss medication for the broader population.CAS 920014-72-8 (Setmelanotide) Its use is carefully determined based on genetic testing confirming the underlying cause of obesity.Setmelanotide acetate | peptide-based agonist of ... The Setmelanotide indication is strictly for individuals with the aforementioned genetic deficiencies.

The development of Setmelanotide also involves considerations regarding its costWO2019099735A1 - Sustained release peptide formulations. As a highly specialized and novel therapy, Setmelanotide (Imcivree®) is one of the costliest medications to treat obesity. However, for eligible patients, it offers a targeted and effective solution that addresses the root cause of their condition, potentially leading to significant improvements in satiety scores and weight-related outcomes.

In summary, Setmelanotide peptide is a cutting-edge therapeutic agent that exemplifies the progress in precision medicine for obesity.Setmelanotide: A Melanocortin-4 Receptor Agonist for the ... Its role as a selective melanocortin 4 receptor (MC4R) agonist and its peptide nature make it a unique and vital treatment option for individuals battling obesity caused by specific genetic defects, offering hope and improved health outcomes.Setmelanotide, sold under the brand name Imcivree,is a medication used for the treatment of genetic obesitycaused by a rare single-gene mutation.